S. 148 118th Congress
Stop STALLING Act
Latest action, Mar 1, 2023: Placed on Senate Legislative Calendar under General Orders. Calendar No. 21.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
8 cosponsors
Sponsored by Amy Klobuchar (Democrat). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
5 D · 3 R
- Democrat
- Republican
- Independent
Referred to: Senate: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
8 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
8 reports
8 reports
GENENTECH, INC.
MARSHALL & POPP, LLC
8 reports
8 reports
8 reports
PFIZER, INC.
MARSHALL & POPP, LLC
8 reports
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
MARSHALL & POPP, LLC
8 reports
8 reports
SANOFI U.S. SERVICES, INC.
MARSHALL & POPP, LLC
8 reports
7 reports
All 25 of 33 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 8 | $24.8M | Q1 2023 | Q3 2024 | yes | |
| AMGEN INC | 8 | $22.9M | Q1 2023 | Q3 2024 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 8 | $15.7M | Q1 2023 | Q3 2024 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 8 | $142.2M | Q1 2023 | Q3 2024 | yes | |
| GENENTECH, INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 8 | $9.9M | Q1 2023 | Q3 2024 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 8 | $551K | Q1 2023 | Q3 2024 | yes | |
| PFIZER, INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 8 | $58.1M | Q1 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| PREMIER, INC. | 8 | $1.7M | Q1 2023 | Q3 2024 | yes | |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | 8 | $480K | Q1 2023 | Q3 2024 | yes |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | 7 | $28.0M | Q1 2023 | Q3 2024 | yes | |
| PUBLIC CITIZEN | 7 | $510K | Q1 2023 | Q3 2024 | yes | |
| AARP | 6 | $28.0M | Q1 2023 | Q2 2024 | yes | |
| NOVARTIS | 6 | $10.0M | Q1 2023 | Q3 2024 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 5 | $8.1M | Q1 2023 | Q3 2024 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 5 | $120K | Q4 2023 | Q3 2024 | yes |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 4 | $710K | Q1 2023 | Q2 2024 | yes | |
| GUIDEWELL MUTUAL HOLDING CORPORATION | 4 | $30K | Q1 2023 | Q2 2024 | yes | |
| PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | COVINGTON & BURLING LLP | 4 | $0 | Q1 2023 | Q3 2024 | yes |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 3 | $180K | Q4 2024 | Q3 2024 | yes |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | 2 | $980K | Q1 2023 | Q2 2023 | yes | |
| BCBSM INC | 2 | $62K | Q2 2024 | Q3 2024 | yes |